{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:38:49Z","timestamp":1791049129424,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02532"],"award-info":[{"award-number":["2018-02532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["Alzheimer Drug Discovery FoundationAlzheimer Drug Discovery Foundation"],"award-info":[{"award-number":["Alzheimer Drug Discovery FoundationAlzheimer Drug Discovery Foundation"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u00c5hl\u00e9ns Stiftelse"},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-720931"],"award-info":[{"award-number":["ALFGBG-720931"]}]},{"DOI":"10.13039\/100010815","name":"Demensf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synaptic pathology is a central event in Alzheimer\u2019s disease (AD) and other neurodegenerative conditions, and investigation of synaptic proteins can provide valuable tools to follow synaptic dysfunction and loss in these diseases. Neuroligin-1 (Nlgn1) is a postsynaptic cell adhesion protein, important for synapse stabilization and formation. Nlgn1 has been connected to cognitive disorders, and specifically to AD, as target of the synaptotoxic effect of amyloid-\u03b2 (A\u03b2) oligomers and A\u03b2 fibrils. To address changes in Nlgn1 expression in human brain, brain regions in different neurological disorders were examined by Western blot and mass spectrometry. Brain specimens from AD (n\u2009=\u200923), progressive supranuclear palsy (PSP, n\u2009=\u200911), corticobasal degeneration (CBD, n\u2009=\u200910), and Pick\u2019s disease (PiD, n\u2009=\u20099) were included. Additionally, cerebrospinal fluid (CSF) samples of AD patients (n\u2009=\u200943) and non-demented controls (n\u2009=\u200942) were analysed. We found decreased levels of Nlgn1 in temporal and parietal cortex (~\u200950\u201360% reductions) in AD brains compared with controls. In frontal grey matter the reduction was not seen for AD patients; however, in the same region, marked reduction was found for PiD (~\u200977%), CBD (~\u200966%) and to a lesser extent for PSP (~\u200943%), which could clearly separate these tauopathies from controls. The Nlgn1 level was reduced in CSF from AD patients compared to controls, but with considerable overlap. The dramatic reduction of Nlgn1 seen in the brain extracts of tauopathies warrants further investigation regarding the potential use of Nlgn1 as a biomarker for these neurodegenerative diseases.<\/jats:p>","DOI":"10.1186\/s40478-021-01119-4","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T08:04:02Z","timestamp":1612166642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-0192","authenticated-orcid":false,"given":"Elena","family":"Camporesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammaryn","family":"Lashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"6","key":"1119_CR1","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1523\/JNEUROSCI.1548-17.2017","volume":"38","author":"C-L Tao","year":"2018","unstructured":"Tao C-L et al (2018) Differentiation and characterization of excitatory and inhibitory synapses by cryo-electron tomography and correlative microscopy. J Neurosci 38(6):1493\u20131510","journal-title":"J Neurosci"},{"key":"1119_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/247150","volume":"2012","author":"W Yu","year":"2012","unstructured":"Yu W, Lu B (2012) Synapses and dendritic spines as pathogenic targets in Alzheimer\u2019s disease. Neural Plast 2012:1\u20138","journal-title":"Neural Plast"},{"key":"1119_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298:789\u2013791","journal-title":"Science"},{"key":"1119_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2005-7203","volume":"7","author":"PH Reddy","year":"2005","unstructured":"Reddy PH et al (2005) Differential loss of synaptic proteins in Alzheimer\u2019s disease: Implications for synaptic dysfunction. J Alzheimer\u2019s Dis 7:103\u2013117","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"4","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD et al (1991) Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572\u2013580","journal-title":"Ann Neurol"},{"issue":"5","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol 27(5):457\u2013464","journal-title":"Ann Neurol"},{"issue":"4","key":"1119_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505\u2013508","journal-title":"JAMA Neurol"},{"issue":"9533","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368(9533):387\u2013403","journal-title":"Lancet"},{"issue":"6","key":"1119_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/jnc.13713","volume":"138","author":"K Lepeta","year":"2016","unstructured":"Lepeta K et al (2016) Synaptopathies: synaptic dysfunction in neurological disorders a review from students to students. J Neurochem 138(6):785\u2013805","journal-title":"J Neurochem"},{"issue":"4","key":"1119_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bcp.2013.12.028","volume":"88","author":"SW Scheff","year":"2014","unstructured":"Scheff SW, Neltner JH, Nelson PT (2014) Is synaptic loss a unique hallmark of Alzheimer\u2019s disease? Biochem Pharmacol 88(4):517\u2013528","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.celrep.2017.03.013","volume":"18","author":"JS Jackson","year":"2017","unstructured":"Jackson JS et al (2017) Altered synapse stability in the early stages of tauopathy. Cell Rep 18(13):3063\u20133068","journal-title":"Cell Rep"},{"issue":"6","key":"1119_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic B et al (2018) Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100(6):1322-1336 e7","journal-title":"Neuron"},{"issue":"7","key":"1119_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","volume":"38","author":"ME Orr","year":"2017","unstructured":"Orr ME, Sullivan AC, Frost B (2017) A brief overview of tauopathy: causes, consequences, and therapeutic strategies. Trends Pharmacol Sci 38(7):637\u2013648","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1515\/tnsci-2015-0023","volume":"6","author":"S Jadhav","year":"2015","unstructured":"Jadhav S et al (2015) Tau-mediated synaptic damage in Alzheimer\u2019s disease. Transl Neurosci 6(1):214\u2013226","journal-title":"Transl Neurosci"},{"issue":"6","key":"1119_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"BR Hoover","year":"2010","unstructured":"Hoover BR et al (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68(6):1067\u20131081","journal-title":"Neuron"},{"issue":"3","key":"1119_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S et al (2016) CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3(3):154\u2013165","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"1119_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1119_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E et al (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56(1):127\u2013129","journal-title":"Neurology"},{"key":"1119_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E et al (2020) Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights 15:1\u201317","journal-title":"Biomark Insights"},{"issue":"1","key":"1119_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng1136","volume":"34","author":"S Jamain","year":"2003","unstructured":"Jamain S et al (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34(1):27\u201329","journal-title":"Nat Genet"},{"issue":"5","key":"1119_CR21","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1074\/jbc.271.5.2676","volume":"271","author":"K Ichtchenko","year":"1996","unstructured":"Ichtchenko K, Nguyen T, S\u00fcdhof TC (1996) Structures, alternative splicing, and neurexin binding of multiple neuroligins. J Biol Chem 271(5):2676\u20132682","journal-title":"J Biol Chem"},{"issue":"1","key":"1119_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tins.2005.11.003","volume":"29","author":"C Dean","year":"2006","unstructured":"Dean C, Dresbach T (2006) Neuroligins and neurexins: linking cell adhesion, synapse formation and cognitive function. Trends Neurosci 29(1):21\u201329","journal-title":"Trends Neurosci"},{"key":"1119_CR23","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1073\/pnas.96.3.1100","volume":"96","author":"JYIK Song","year":"1999","unstructured":"Song JYIK, S\u00fcdhof TC, Brose N (1999) Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proc Natl Acad Sci 96:1100\u20131105","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1119_CR24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.neuron.2007.12.002","volume":"56","author":"D Arac","year":"2007","unstructured":"Arac D et al (2007) Structures of neuroligin-1 and the neuroligin-1\/neurexin-1 beta complex reveal specific protein-protein and protein-Ca2+ interactions. Neuron 56(6):992\u20131003","journal-title":"Neuron"},{"issue":"5713","key":"1119_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.1107470","volume":"307","author":"B Chih","year":"2005","unstructured":"Chih B, Engelman H, Scheiffele P (2005) Control of excitatory and inhibitory synapse formation by neuroligins. Science 307(5713):1324\u20131328","journal-title":"Science"},{"issue":"6","key":"1119_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.neuron.2006.09.003","volume":"51","author":"F Varoqueaux","year":"2006","unstructured":"Varoqueaux F et al (2006) Neuroligins determine synapse maturation and function. Neuron 51(6):741\u2013754","journal-title":"Neuron"},{"issue":"1","key":"1119_CR27","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1038\/s41467-018-06220-2","volume":"9","author":"M Letellier","year":"2018","unstructured":"Letellier M et al (2018) A unique intracellular tyrosine in neuroligin-1 regulates AMPA receptor recruitment during synapse differentiation and potentiation. Nat Commun 9(1):3979","journal-title":"Nat Commun"},{"key":"1119_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1749-8104-4-17","volume":"4","author":"SL Barrow","year":"2009","unstructured":"Barrow SL et al (2009) Neuroligin1: a cell adhesion molecule that recruits PSD-95 and NMDA receptors by distinct mechanisms during synaptogenesis. Neural Dev 4:17","journal-title":"Neural Dev"},{"issue":"2","key":"1119_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1073\/pnas.1214718110","volume":"110","author":"EC Budreck","year":"2013","unstructured":"Budreck EC et al (2013) Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling. Proc Natl Acad Sci USA 110(2):725\u2013730","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1119_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.neuron.2019.02.013","volume":"102","author":"X Wu","year":"2019","unstructured":"Wu X et al (2019) Neuroligin-1 signaling controls LTP and NMDA receptors by distinct molecular pathways. Neuron 102(3):621-635.e3","journal-title":"Neuron"},{"issue":"3","key":"1119_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/mcne.1998.0679","volume":"11","author":"C Kurschner","year":"1998","unstructured":"Kurschner C et al (1998) CIPP a novel multivalent PDZ domain protein , selectively interacts with Kir4.0 family members, NMDA receptor subunits, neurexins, and neuroligins. Mol Cell Neurosci 11(3):161\u2013172","journal-title":"Mol Cell Neurosci"},{"issue":"2","key":"1119_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2012.10.003","volume":"76","author":"K Suzuki","year":"2012","unstructured":"Suzuki K et al (2012) Activity-dependent proteolytic cleavage of neuroligin-1. Neuron 76(2):410\u2013422","journal-title":"Neuron"},{"issue":"2","key":"1119_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuron.2012.07.006","volume":"76","author":"RT Peixoto","year":"2012","unstructured":"Peixoto RT et al (2012) Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuron 76(2):396\u2013409","journal-title":"Neuron"},{"issue":"4","key":"1119_CR34","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s12035-018-1243-1","volume":"56","author":"JJ Chmielewska","year":"2019","unstructured":"Chmielewska JJ et al (2019) Neuroligin 1, 2, and 3 regulation at the synapse: FMRP-dependent translation and activity-induced proteolytic cleavage. Mol Neurobiol 56(4):2741\u20132759","journal-title":"Mol Neurobiol"},{"key":"1119_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fnsyn.2015.00011","volume":"7","author":"F Espinosa","year":"2015","unstructured":"Espinosa F et al (2015) Neuroligin 1 modulates striatal glutamatergic neurotransmission in a pathway and NMDAR subunit-specific manner. Front Synaptic Neurosci 7:11","journal-title":"Front Synaptic Neurosci"},{"issue":"1","key":"1119_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00429-013-0636-1","volume":"220","author":"P Jedlicka","year":"2015","unstructured":"Jedlicka P et al (2015) Neuroligin-1 regulates excitatory synaptic transmission, LTP and EPSP-spike coupling in the dentate gyrus in vivo. Brain Struct Funct 220(1):47\u201358","journal-title":"Brain Struct Funct"},{"issue":"6","key":"1119_CR37","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1523\/JNEUROSCI.4517-09.2010","volume":"30","author":"J Blundell","year":"2010","unstructured":"Blundell J et al (2010) Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci 30(6):2115\u20132129","journal-title":"J Neurosci"},{"issue":"6","key":"1119_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.neuron.2007.05.029","volume":"54","author":"AA Chubykin","year":"2007","unstructured":"Chubykin AA et al (2007) Activity-dependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron 54(6):919\u2013931","journal-title":"Neuron"},{"key":"1119_CR39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature07456","volume":"455","author":"TC S\u00fcdhof","year":"2008","unstructured":"S\u00fcdhof TC (2008) Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455:903\u2013911","journal-title":"Nature"},{"key":"1119_CR40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fphys.2012.00464","volume":"3","author":"MC Dinamarca","year":"2012","unstructured":"Dinamarca MC, Rios JA, Inestrosa NC (2012) Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer\u2019s disease. Front Physiol 3:464","journal-title":"Front Physiol"},{"key":"1119_CR41","first-page":"6427537","volume":"2016","author":"I Leshchyns'ka","year":"2016","unstructured":"Leshchyns\u2019ka I, Sytnyk V (2016) Synaptic cell adhesion molecules in Alzheimer\u2019s disease. Neural Plast 2016:6427537","journal-title":"Neural Plast"},{"issue":"2","key":"1119_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nn.3618","volume":"17","author":"B Bie","year":"2014","unstructured":"Bie B et al (2014) Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat Neurosci 17(2):223\u2013231","journal-title":"Nat Neurosci"},{"issue":"18","key":"1119_CR43","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1074\/jbc.M116.761189","volume":"292","author":"J Brito-Moreira","year":"2017","unstructured":"Brito-Moreira J et al (2017) Interaction of amyloid-beta (Abeta) oligomers with neurexin 2alpha and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem 292(18):7327\u20137337","journal-title":"J Biol Chem"},{"issue":"1","key":"1119_CR44","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbrc.2015.08.107","volume":"466","author":"MC Dinamarca","year":"2015","unstructured":"Dinamarca MC et al (2015) The soluble extracellular fragment of neuroligin-1 targets Abeta oligomers to the postsynaptic region of excitatory synapses. Biochem Biophys Res Commun 466(1):66\u201371","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1119_CR45","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.1038\/s41598-020-63255-6","volume":"10","author":"J Dufort-Gervais","year":"2020","unstructured":"Dufort-Gervais J et al (2020) Neuroligin-1 is altered in the hippocampus of Alzheimer\u2019s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers. Sci Rep 10(1):6956","journal-title":"Sci Rep"},{"issue":"4","key":"1119_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389\u2013404","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1119_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/alzrt254","volume":"6","author":"ME Murray","year":"2014","unstructured":"Murray ME, Dickson DW (2014) Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer\u2019s disease? Alzheimers Res Ther 6(3):24","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1119_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT et al (2012) National institute on aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8(1):1\u201313","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1119_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol 123(1):1\u201311","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1119_CR50","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G et al (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"4","key":"1119_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS et al (1991) The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology. 41(4):479\u2013486","journal-title":"Neurology."},{"issue":"9","key":"1119_CR52","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","volume":"39","author":"JC Morris","year":"1989","unstructured":"Morris JC et al (1989) The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology. 39(9):1159\u20131165","journal-title":"Neurology."},{"issue":"12","key":"1119_CR53","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR et al (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791\u20131800","journal-title":"Neurology"},{"issue":"7","key":"1119_CR54","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archneur.1995.00540310076019","volume":"52","author":"JM Olichney","year":"1995","unstructured":"Olichney JM et al (1995) Cerebral infarction in Alzheimer\u2019s disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 52(7):702\u2013708","journal-title":"Arch Neurol"},{"issue":"1","key":"1119_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12208","volume":"41","author":"GG Kovacs","year":"2015","unstructured":"Kovacs GG (2015) Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41(1):3\u201323","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1119_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie IR et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1\u20134","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1119_CR57","first-page":"29","volume":"32","author":"T Benaglia","year":"2009","unstructured":"Benaglia T et al (2009) mixtools: An R package for analyzing mixture. Models 32(6):29","journal-title":"Models"},{"issue":"4","key":"1119_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3233\/JAD-190187","volume":"69","author":"K Minta","year":"2019","unstructured":"Minta K et al (2019) Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer\u2019s disease. J Alzheimers Dis 69(4):1213\u20131220","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1119_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG et al (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol 71(4):266\u2013273","journal-title":"J Neuropathol Exp Neurol"},{"issue":"23","key":"1119_CR60","doi-asserted-by":"publisher","first-page":"e1800236","DOI":"10.1002\/pmic.201800236","volume":"18","author":"JK Goodman","year":"2018","unstructured":"Goodman JK et al (2018) Updates of the in-gel digestion method for protein analysis by mass spectrometry. Proteomics 18(23):e1800236","journal-title":"Proteomics"},{"issue":"11","key":"1119_CR61","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1021\/ac035286f","volume":"76","author":"J Havlis","year":"2004","unstructured":"Havlis J, Shevchenko A (2004) Absolute quantification of proteins in solutions and in polyacrylamide gels by mass spectrometry. Anal Chem 76(11):3029\u20133036","journal-title":"Anal Chem"},{"issue":"2","key":"1119_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.neuron.2005.08.026","volume":"48","author":"AA Boucard","year":"2005","unstructured":"Boucard AA et al (2005) A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron 48(2):229\u2013236","journal-title":"Neuron"},{"issue":"12","key":"1119_CR63","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA et al (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66(12):1837\u20131844","journal-title":"Neurology"},{"issue":"11","key":"1119_CR64","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman DS et al (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62(11):1087\u20131095","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"1119_CR65","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0197-4580(91)90006-6","volume":"12","author":"JL Price","year":"1991","unstructured":"Price JL et al (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer\u2019s disease. Neurobiol Aging 12(4):295\u2013312","journal-title":"Neurobiol Aging"},{"issue":"6","key":"1119_CR66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnen\/nlw026","volume":"75","author":"A Serrano-Pozo","year":"2016","unstructured":"Serrano-Pozo A et al (2016) Thal Amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J Neuropathol Exp Neurol 75(6):516\u2013526","journal-title":"J Neuropathol Exp Neurol"},{"key":"1119_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419888819","volume":"12","author":"M Mila-Aloma","year":"2019","unstructured":"Mila-Aloma M, Suarez-Calvet M, Molinuevo JL (2019) Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease. Ther Adv Neurol Disord 12:1\u201323","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"1119_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362\u2013381","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1119_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17(1):5\u201321","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"1119_CR70","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","volume":"22","author":"DJ Irwin","year":"2016","unstructured":"Irwin DJ (2016) Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 22(Suppl 1):S29-33","journal-title":"Parkinsonism Relat Disord"},{"key":"1119_CR71","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","volume":"24","author":"VM Lee","year":"2001","unstructured":"Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121\u20131159","journal-title":"Annu Rev Neurosci"},{"issue":"5","key":"1119_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton NJ et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16(5):265\u2013284","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1119_CR73","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/joim.12164","volume":"275","author":"X Li","year":"2014","unstructured":"Li X et al (2014) The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer\u2019s disease. J Intern Med 275(4):418\u2013427","journal-title":"J Intern Med"},{"issue":"Suppl 1","key":"1119_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K (2017) A review of fluid biomarkers for Alzheimer\u2019s disease: moving from CSF to blood. Neurol Ther 6(Suppl 1):15\u201324","journal-title":"Neurol Ther"},{"issue":"4","key":"1119_CR75","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.neurobiolaging.2013.09.032","volume":"35","author":"IA Sindi","year":"2014","unstructured":"Sindi IA, Tannenberg RK, Dodd PR (2014) Role for the neurexin-neuroligin complex in Alzheimer\u2019s disease. Neurobiol Aging 35(4):746\u2013756","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1119_CR76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/nmt.14.54","volume":"5","author":"IA Sindi","year":"2015","unstructured":"Sindi IA, Dodd PR (2015) New insights into Alzheimer\u2019s disease pathogenesis: the involvement of neuroligins in synaptic malfunction. Neurodegener Dis Manag 5(2):137\u2013145","journal-title":"Neurodegener Dis Manag"},{"issue":"12","key":"1119_CR77","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1016\/j.neurobiolaging.2015.09.004","volume":"36","author":"E Tristan-Clavijo","year":"2015","unstructured":"Tristan-Clavijo E et al (2015) A truncating mutation in Alzheimer\u2019s disease inactivates neuroligin-1 synaptic function. Neurobiol Aging 36(12):3171\u20133175","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1119_CR78","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1096\/fj.201700731R","volume":"32","author":"EJ Goetzl","year":"2018","unstructured":"Goetzl EJ et al (2018) Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer\u2019s disease. FASEB J 32(2):888\u2013893","journal-title":"FASEB J"},{"issue":"3","key":"1119_CR79","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lleo","year":"2019","unstructured":"Lleo A et al (2019) Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteomics 18(3):546\u2013560","journal-title":"Mol Cell Proteomics"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-021-01119-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T08:14:20Z","timestamp":1612167260000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-021-01119-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1186\/s40478-021-01119-4","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"2 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory board for Axon, Biogen, CogRx, Lilly, MegQu, Novartis and Roche Diagnostics. OH has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and AVID Radiopharmaceuticals. In the past 2\u00a0years, he has received consultancy\/speaker fees (paid to the institution) from Biogen and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}